Message #43 From:
NewsBot Date: November 10, 2005 03:20:00 AM
CLXN News CLX Investment Company CEO Comments on Zonda Market Potential in the Wake of New Infectious Disease Statistics
TEMECULA, Calif.--(BUSINESS WIRE)--Nov. 10, 2005--CLX Investment Company, Inc. (OTCBB:CLXN) chief executive officer Tammy D. Dunn today commented on new statistics released this week by the United States Center for Disease Control (CDC), which show an increased need to address rising Chlamydia infection rates and early detection of all infectious diseases.
"This information released by the CDC illustrates that our Zonda portfolio investment is well-positioned in a market certain to expand as the demand for more rapid and effective diagnostic methods for infectious diseases grows," commented Ms. Dunn. "Chlamydia is a serious and growing problem around the world, particularly in places like Africa, where it is a leading cause of blindness in children."
Zonda, Inc., a privately held company that specializes in test products that serve the medical diagnostic (IVD), food safety, and sanitation testing markets, is expanding the distribution of its product lines into broader markets around the world, with the first product that has been targeted for accelerated marketing and distribution efforts is an innovative, rapid, self-contained diagnostic device for the detection of Chlamydia. The device, which is marketed under the HandiLab name, is superior to its competition due to its comparable accuracy (compared directly to PCR testing), ease of use, compact design, long shelf life, rapid results, and cost effectiveness.
"CLX is providing Zonda with the financing and management support necessary to increase distribution of its HandiLab-C test for Chlamydia, as well as additional diagnostic products for Gonorrhea, Yeast and Strep A, in order to meet the growing need for on-the-spot diagnostic tools for both health care facilities and the over-the-counter markets. We are pleased to see this issue begin to get the attention that it deserves from both the CDC and the media, and we expect that there will be more focus on the dangers of infectious disease and the critical need for early detection in the future. Our goal with this portfolio investment is to provide the resources necessary for Zonda to become the preferred provider worldwide of rapid, self-contained diagnostic tests for the infectious diseases," added Ms. Dunn.
To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.asp.
About the Company
CLX Investment Company (www.clxinvestments.com) has elected to be regulated as a Business Development Company pursuant to Section 54 of the Investment Company Act of 1940, and is pursuing a business plan wherein the Company seeks to make investment in developing companies with the goal of providing return for its shareholders.
CLX has acquired a 49% interest in eStrategy Solutions, Inc. (www.clxinvestments.com/estrategysolutions), a Texas-based e-learning provider that has developed online training solutions for government entities and other professional organizations. The Company has made an investment in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards. CLX holds a 20% equity interest in Zonda, Inc. (www.zondainc.com), a privately held company that specializes in test products that serve the medical diagnostic, bacterial food testing and environmental surfaces testing markets.
All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investment's control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.
